

1 **Vaccine-preventable diseases other than tuberculosis, and homelessness: A systematic**
2 **review of the published literature, 1980 to 2020**

3 Tran Duc Anh Ly^{1,2}, Sergei Castaneda², Van Thuan Hoang^{1,2,3}, Thi Loi Dao^{1,2,4}, Philippe
4 Gautret^{1,2*}

5 1.Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.

6 2.IHU-Méditerranée Infection, Marseille, France.

7 ³Family Medicine Department, Thai Binh University of Medicine and Pharmacy, Vietnam

8 ⁴Pneumology Department, Thai Binh University of Medicine and Pharmacy, Vietnam

9 ***Corresponding author:** Philippe Gautret, VITROME, Institut Hospitalo-Universitaire
10 Méditerranée Infection, 19-21 Boulevard Jean Moulin 13385 Marseille Cedex 05, France. Phone: + 33 (0)
11 4 13 73 24 01. Fax: + 33 (0) 4 13 73 24 02.

12 Email address: philippe.gautret@club-internet.fr

13

14 **Keywords.** Homelessness, outbreak, vaccine-preventable diseases, immunization, vaccination
15 recommendation.

16

17 **Abstract (265/300 words)**

18 **Background.** Homelessness may result in the breakdown of regular health services, including
19 routine vaccination programmes. A literature review was conducted to describe vaccine-preventable
20 diseases (VPD) other than tuberculosis in homeless populations and to summarize vaccination
21 recommendations in homeless people.

22 **Methods.** We followed Preferred Reporting Items for Systematic reviews and Meta-Analyses
23 (PRISMA) guidelines. We searched peer-reviewed literature published in English, French or Spanish
24 reporting the outbreak of VPD or VPD prevalence in both infant and adult homeless populations
25 published between 1980 and 2020, using PubMed/Medline, SciELO, Google Scholar, and Web of
26 Science databases. Relevant information from the studies was charted in Microsoft Excel and results
27 were summarised using a descriptive analytical method.

28 **Results.** Seventy-five articles were included. A high prevalence of past HBV and HAV
29 infections were observed through serosurveys, mostly in high income countries or high-middle income
30 countries (USA, Canada, France, Iran or Brazil). Nine outbreaks of HAV infection were also reported,
31 with lethality rates ranging from 0-4.8%. The studies discussed numerous risk factors positively
32 associated with HBV infection, including older age, homosexual or bisexual practice, injected drug use
33 (IDU), and, with HAV infection including IDU, having sexual partner(s) with a history of unspecified
34 hepatitis, insertive anal penetration, or originating from a country with a high prevalence of anti-HAV
35 antibody. Eleven outbreaks of pneumococcal infection affecting homeless persons were reported in
36 Canada and USA, with lethality rates from 0-15.6%. Five diphtheria outbreaks were reported.
37 Vaccination status was rarely documented in these studies.

38 **Conclusions.** The literature suggests that homeless populations generally experience a higher
39 VPD burden and lower immunisation rates. The findings suggest the need for a national vaccination
40 programme and planning for delivering vaccines in this population.

41

42 **Main text (3024/5000 words)**

43 **1. Introduction.**

44 In addition to mental illness and unintentional injuries, homeless people are exposed to
45 communicable diseases, which may lead to outbreaks that can become serious public health concerns
46 [1]. High rates of infectious disease have been recorded in the literature among homeless people,
47 including respiratory tract infections [2], gastrointestinal infections [3], skin infections, arthropod-
48 borne diseases [4], and blood-borne and sexually transmitted infections [1].

49 The prevalence of these infectious diseases among the homeless varies greatly, depending on
50 exposure factors. Generally, frequent alcohol and tobacco consumption or illicit drug use significantly
51 impair the health status of homeless individuals [1]. Those sleeping on the street, outdoors in vehicles
52 or in abandoned buildings are at high risk of food-borne disease (as the result of exposure to
53 unhygienic environments) [3], human louse-transmitted disease [5], and of blood-borne and sexually
54 transmitted infections (as the result of promiscuity and lack of hygiene, injected drug use and
55 unprotected sexual practices) [6-7]. In addition, living in overcrowded accommodations, poor
56 environmental conditions (poor ventilation, lack of sufficient food) and lack of continuity of care
57 (omission of preventive measures, delayed diagnosis, interrupted or poor quality treatment) may
58 increase vulnerability to infection, including transmissible disease. Consequently, when outbreaks
59 occur in these settings, they spread rapidly, often with a high probability of prolonged transmission [1].

60 Evidence suggests that vaccination is still the most effective strategy for preventing infectious
61 disease, resulting in significant reductions in illness, disability and death from several VPD [8].
62 Implementing routine vaccination may not only ensure long-term protection against VPD through the
63 progressive increase of population immunity, limiting the number of preventable deaths among
64 homeless people during an outbreak [3], but also protects vulnerable members of the general
65 population who have not received all vaccines, such as the immunocompromised and the very young
66 [9].

67 TB in homeless people has been extensively described in several recent review papers [10-13].
68 This scoping review of the published literature aims to describe an outbreak of VPD or VPD

69 prevalence other than TB in both an infant and adult homeless population during the period 1980-
70 2020. In addition, vaccination recommendations in homeless people were reviewed.

71 **2. Materials and Methods**

72 **2.2 Search strategy.** The systematic review followed the Preferred Reporting Items for
73 Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<http://www.prisma-statement.org>).
74 Using Harzing's Publish or Perish software (version 7.0), we searched the published literature from
75 1980 to 04 September 2020 in PubMed/Medline (in English), Scopus (in English), Web of Science
76 databases (in English), SciELO (in English and Spanish), and Google Scholar (in French). Search
77 strings were tailored to each database. Article references were scanned for additional articles.
78 References were managed by Endnote software (version 9.3), and relevant information from the
79 studies was charted in Microsoft Excel. Data table elements were created and were reviewed by all
80 authors to ensure consistency of information extraction. Combinations of the following English search
81 terms were used:

82 #1: "homeless" OR "homelessness" OR "street people"

83 #2: "diphtheria" OR "*Corynebacterium diphtheriae*" OR "tetanus" OR "*Condyloma*
84 *acuminata*" OR "polio" OR "poliovirus" OR "poliomyelitis" OR "pertussis" OR "whooping cough"
85 OR "*Bordetella pertussis*" OR "*Haemophilus influenzae* type b" OR "hepatitis B" OR
86 "pneumococcal" OR "*Streptococcus pneumoniae*" OR "meningococcal" OR "meningococcus" OR
87 "*Neisseria meningitidis*" OR "mumps" OR "measles" OR "rubella" OR "Human papillomavirus" OR
88 "influenza" OR "flu" OR "hepatitis A" OR "shingles" OR "Varicella" OR "chickenpox" OR
89 "typhoid" OR "Salmonella" OR "Rotavirus" OR "cholera" OR "*Vibrio cholerae*" OR "yellow fever"
90 OR "rabies" OR "lyssaviruses" OR "Japanese encephalitis" OR "leptospirosis" OR "Leptospira"

91 #3: #1 AND #2

92 Combinations of the search terms in Spanish and French are shown in Supplementary data.

93 **2.3 Inclusion and exclusion criteria.** For inclusion, an article had to fulfil the following criteria:
94 articles (1) written in English (focused language), French, Spanish, or Portuguese languages (if any);
95 (2) published in peer-reviewed journals or unpublished data in our laboratory regarding the homeless
96 population in Marseille, France; (3) reporting outbreaks of VPD or VPD prevalence in an infant or

97 adult homeless population. Articles were excluded if the studies were reviews, case reports, or reported
98 only vaccination rates. An additional manual search was conducted by reviewing reference lists of
99 papers retrieved through the electronic search.

100 **3. Results**

101 As presented in Figure 1, the search identified a total of 9499 records, with an additional 2
102 records being unpublished data in our laboratory, resulting in 75 articles/reports that fulfilled the
103 eligibility criteria (Figure 1). Seventy-one were written in English, one in French and two in Spanish.
104 One article written in Portuguese was found when searching abstracts in English and was also
105 included. The main findings of these articles are presented in Table 1.

106 **Hepatitis B (Table 1)**

107 Forty-two hepatitis B articles reporting on vulnerable populations, notably including homeless
108 people, were retrieved (including an unpublished data set) [6, 14-53]. Overall, 269,750 individuals
109 were enrolled between 1988 and 2019. Thirty studies were conducted in adults (mean age: 25-49
110 years, range 16-86 years) [6, 14, 15, 17-25, 29-34, 37-40, 44-47, 49, 51-53], five studies were
111 conducted in street youth (mean age:10-16 years, range 8-18 years) [16, 26-28, 51], and seven in both
112 children and adults (mean age: 14-26 years, range 9-65 years) [35, 36, 41-43, 48, 50]. Studies were
113 conducted in the USA (n=17) [14, 18, 33-35, 38, 40-47, 49, 52, 53], Iran (n=4) [6, 17, 21, 28], Canada
114 [36, 48, 51], Brazil [19, 37, 50] France [15, 16] (including unpublished data), the UK [23, 25, 33],
115 (n=3 per country), Australia [31], Costa Rica [24], Czech Republic [32], Germany [22], India [26],
116 Ireland [29], Peru [20], Philippines [27] and Spain [39] (n=1 per country). Forty studies were
117 seroprevalence surveys [6, 14-19, 21-42, 44-53]. The prevalence of anti-HBc antibodies ranged from
118 10.4% to 80.3% (past infection) and that of HBsAg ranged from 0.6% to 4.7% (ongoing infection).
119 Two retrospective questionnaire surveys reported rates of 1.6% and 6% for HBV infection among
120 participants [20, 43]. HBV infection among the homeless population was significantly higher than in
121 non-homeless individuals included in the studies, or than in the general population, as assessed in
122 studies conducted at the same period (n=14, including one unpublished data set) [16, 18, 19, 22, 31,
123 32, 36, 42, 47, 48, 51-53].

124 HBV infection among the homeless population was shown to be positively associated with older
125 age [19, 42, 48], with homosexual or bisexual practices, having a sexual partner(s) with a history of
126 unspecified hepatitis or insertive anal penetration [19, 42, 48], having black skin colour [19], reporting
127 injected drug use (IDU) [6, 22-24, 29-33, 35, 38, 39, 41, 44, 48, 49], and alcohol use [33]. One study
128 conducted among 189 homeless individuals in Australia reported that 6.3% of individuals with a past
129 HBV infection also had a past hepatitis A (HAV) infection [31]. No hepatitis B-related deaths were
130 reported. Five studies reported vaccination status against HBV infection through a questionnaire, with
131 rates of 9%-54% (at least one dose) and 11.8%->66% (3 doses) [22, 30, 43, 44, 46, 48], and three
132 studies showed immunisation rates of 21.8%-38.7% through serological tests [19, 23]. Anti-HBV
133 vaccination was strongly recommended by all authors for high risk groups such as street youth or
134 injected drug users (n=24 studies, including unpublished data) [15, 16, 19, 22, 23, 31, 32, 35-37, 39-
135 44, 46-48, 50-53].

136 **Hepatitis A (Table 2)**

137 Seventeen hepatitis A articles conducted among homeless populations fulfilled the eligibility
138 criteria [31, 35, 36, 54-67]. Overall, 10,552 individuals were enrolled between 1991 and 2018. Nine
139 studies were conducted in adults (mean age: 19-45 years, range 16-74 years) [31, 55-57, 59, 61, 62, 64,
140 65], and eight in populations comprising children and adults (mean age: 25-42 years, range 0-90 years)
141 [35, 36, 54, 58, 60, 63, 66, 67]. Studies were conducted in the USA (n=7) [35, 54, 56-68, 61, 64],
142 Canada (n=4) [36, 55, 65, 66], Brazil [67], the UK [63], Czech Republic [60], The Netherlands [62],
143 Iran [59] and Australia (n=1 per country) [31].

144 Eight surveys addressed the seroprevalence of total anti-HAV antibodies among 6649
145 individuals: six revealed a high prevalence of 19.3%-69.7% among homeless persons in Brazil,
146 Canada and the USA [31, 35, 36, 59, 64, 67], while two studies showed lower seroprevalence rates of
147 4.7%-6.3% among Canadian street youth, but with a high prevalence of risk factors for infection [65,
148 66]. Three studies reported risk factors for a high prevalence of HAV infection (reporting IDU, having
149 sexual partner(s) with history of unspecified hepatitis, male subjects reporting insertive anal
150 penetration or those originating from a country with a high anti-HAV prevalence) [35, 65, 66]. Other
151 studies described nine outbreaks of Hepatitis A in several cities in the UK, The Netherlands, Czech

152 republic and the USA; the numbers of confirmed cases in hospitals ranged from 42 to 1521 per
153 outbreak (resulting in a total of 3903 outbreak-associated cases), with a high prevalence of 15.1%-
154 78.0% being homeless persons [54-58, 60-63]. HAV-associated deaths ranged from 0-4.8% during
155 outbreaks. Rates of co-infection with HAV and HBV (or HCV) were 3.0%, 6.3% and 34.0% in three
156 studies [31, 55, 58]. No data about previous vaccination rates were available. Vaccination of homeless
157 populations against HAV was strongly recommended in 15 studies [31, 35, 36, 54-56, 58, 60-67].

158 **Pneumococcal infections (Table 3)**

159 Thirteen studies concerning pneumococcal infections in homeless people were retrieved between
160 1988 and 2017 (including one unpublished data set) [2, 68-78]: 12 studies were conducted in adults
161 (mean age: 19-54 years, range 16-78 years) and one in a population comprising children and adults
162 (mean age: 42 years, range 0-90 years). Most studies were conducted in Canada (n=8) [68, 70-76],
163 followed by France (n=3, including one unpublished data set) [2, 78], and the USA (n=2) [69, 77].
164 Two molecular prevalence surveys reported rates of 12.4% and 15.5% for pneumococcal
165 nasopharyngeal carriage among a total of 575 sheltered homeless persons in Marseille, France between
166 2015-2018 (including one unpublished data set) [2], and prevalence was positively associated with
167 respiratory symptoms and signs. Other studies described eleven outbreaks of invasive pneumococcal
168 disease (IPD) occurring in different cities in Canada, the USA and France; of those, two studies
169 reported 153 homeless individuals hospitalised with IPD, which accounted for 1.4%-8.4% of all
170 homeless people present in two cities, Toronto (Canada) and Anchorage (USA) [76, 77]; nine other
171 studies reported a high proportion (4.7%-48.8%) of homelessness among 4742 individuals hospitalised
172 with IPD [68-75, 78]. Homeless individuals with IDP were typically younger [73, 77], more often
173 male [73], smokers [73, 75, 76], alcohol abusers [73, 75, 77], illegal drug users [73, 75], and had a
174 primary diagnosis of pneumonia [73], HIV infection or liver disease [76] when compared with non-
175 homeless individuals. Of nine studies, two characterising the serotype of isolated *Streptococcus*
176 *pneumoniae* strains showed that serotypes 1, 4, 5, 8 and 12F were positively associated with
177 homelessness in Canada [68, 70, 72]. A serotype 1 IPD outbreak was reported among sheltered
178 homeless individuals in Paris, France between 1988-1989 [78]. Serotype 4 outbreaks were also
179 positively associated with homelessness in New Mexico, USA [69]. The mortality rate was 0%-15.6%

180 among infected homeless people during outbreaks. By using a questionnaire, previous vaccination
181 rates among the homeless population were reported to be 3.1%-37.0% (including one unpublished data
182 set) [68, 70, 76, 78]. The pneumococcal vaccine was recommended for homeless populations in all
183 articles.

184 **Diphtheria (Table 3)**

185 Five diphtheria outbreak investigations were retrieved between 1972 and 2017. Overall, 1251
186 diphtheria cases were confirmed by culture (with a high prevalence of 12.0%-95.0% cases being
187 homeless persons) [79-83]. Three studies were conducted in adults (mean age: 40-45 years, range 16-
188 >71 years) [79-81], and two in both children and adults (mean age: 37-38 years, range 4-87 years) [82,
189 83]. An early investigation conducted in Seattle, USA between 1972-1982 reported an outbreak of
190 respiratory and cutaneous infections among 1100 patients, including 95% homeless individuals [83].
191 Molecular studies performed in different types of samples (details not provided) collected in Germany
192 and Poland showed a high 53.9%-100% prevalence of genotype ST8 [79, 80]. One study conducted in
193 Switzerland, Germany and France between 1996-1997 reported 17 cases with cutaneous infection [81].
194 One study conducted in France between 1987-1993 reported 40 patients with systemic infection [82].

195 Several risk factors for diphtheria infection were identified, including alcohol abuse [79-81, 83],
196 poor hygiene, crowding conditions, contaminated fomites, underlying skin disease, hyperendemic
197 streptococcal pyoderma, and introduction of new strains from exogenous reservoirs [83]. Death from
198 diphtheria was reported in two studies, with 0.9%-36.0% lethality rates [82, 83]. No data about
199 previous vaccination status was available. One study recommended the need for vaccination boosters
200 in alcoholic homeless persons [83].

201 **Seasonal influenza (Table 3)**

202 Four PCR-based prevalence surveys conducted among 1103 homeless or persons from
203 marginalised populations between 2005 and 2018 fulfilled the eligibility criteria [2, 15, 84, 85]. Three
204 were conducted among adult sheltered homeless persons in Marseille, France, and one was conducted
205 among marginalised populations, including homeless persons, in Tijuana, Mexico. Three studies were
206 conducted in adults (mean age: 35-44 years, range 18-84 years) [2, 15, 84] and one in a population
207 comprising children and adults (mean age: 41 years, range 7-76 years) [85]. These studies reported a

208 1.0-3.0% rate of influenza nasopharyngeal carriage among sheltered homeless persons. Using a
209 questionnaire, the previous seasonal influenza vaccination rate among the homeless population was
210 9.0%-15.0%. The rate of co-infection with *S. pneumoniae* and influenza viruses was 0.2% among
211 homeless individuals in Marseille, France [2]. No influenza deaths were reported. All authors
212 recommended vaccination against influenza for homeless people.

213 **Human papillomavirus (HPV) infection (Table 3)**

214 Only two American studies concerning HPV infection fulfilled the eligibility criteria. They were
215 conducted in young adults (range 16-29 years) [46, 86]. One molecular prevalence survey was
216 conducted among 130 men having sex with men, of whom 22.6% were homeless and 75% had at least
217 one high-risk HPV type [86]. Another epidemiological study using Pap smear testing in 2960 young
218 female homeless persons revealed a 2.0% rate of HPV infection [46]. Information about vaccination
219 rates was not recorded. No deaths were reported. The vaccination against HPV-16 was recommended
220 for homeless men who have sex with men [86].

221 **Other VPD**

222 No reports about measles, tetanus, poliomyelitis, pertussis, *H. influenzae* type b infection,
223 meningococcal C infection, mumps, rubella, varicella, chickenpox, typhoid fever, rotavirus infection,
224 cholera, yellow fever, lyssaviruses, rabies, Japanese encephalitis and leptospirosis among homeless
225 people were retrieved.

226 **4. Discussion**

227 This review shows that the four most frequent VPD among homeless people are HBV infection,
228 HAV infection, IPD, and diphtheria.

229 High rates of HBV and HAV infection in homeless persons were observed through serological
230 surveys in low endemicity countries, including the USA, Canada, France and in moderate endemicity
231 countries such as Iran and Brazil. Outbreaks of HAV infection were reported in the US. Currently,
232 three modes of HBV transmission have been recognised: perinatal, sexual and parenteral/percutaneous
233 transmission [87], whilst acute HAV is a highly contagious infection resulting from faeco-oral
234 transmission and has been one of the major aetiologies for foodborne disease [88]. Homeless persons,
235 notably those using injected drugs and having at-risk sexual practices should therefore benefit from

236 vaccination against HBV and HAV infections, together with the provision of injection kits, drug
237 substitutes and condoms.

238 Outbreaks of IPD were reported in homeless persons in Canada, and several risk factors were
239 identified, including smoking, alcohol abuse, illegal drug use and having several chronic diseases.
240 Given that the serotypes attributable to these outbreaks (1, 4, 5, 8, 12F) are among those included in
241 the 23-valent pneumococcal polysaccharide vaccine, vaccination of homeless people against IPD
242 should be considered, notably when presenting with risk factors.

243 Finally, because of several diphtheria outbreaks occurring among homeless persons, updating
244 vaccination against this disease should be also considered in this population, as in the general
245 population.

246 To the best of our knowledge, specific vaccination recommendations for homeless people in
247 national guidelines have been made in only two countries. The 23-valent pneumococcal
248 polysaccharide vaccine (PPSV23) was recommended early in 2008 by the Canadian National Advisory
249 Committee on Immunization (NACI) for all homeless people. In the USA, the adult immunisation
250 schedule [89], updated annually by the Advisory Committee on Immunization Practices (ACIP), has
251 recommended HAV vaccination for all homeless individuals aged > 1 year since October 2018 [3].

252 In France, the Ministry of Solidarity and Health (Table 4) recommends HAV vaccination for:
253 children aged > 1 year having at least one family member originating from a country with a high
254 prevalence of anti-HAV antibody, for patients with cystic fibrosis or liver disease (notably viral
255 hepatitis and alcohol abuse), for institutionalised infants or young disabled persons, for men having sex
256 with men, for professionals exposed to HAV or involved in collective food preparation and for
257 travellers to endemic areas. For HBV, IPD, and diphtheria, primary vaccination is recommended for all
258 children. The HBV vaccination is notably recommended for institutionalised infants or young disabled
259 persons, for persons in psychiatric institutions, for those with at-risk sexual practices, those using
260 injected drugs or having chronic liver disease or HIV infection, for those with at least one family
261 member with HBV infection, for detained persons, for professionals exposed to HBV (notably health
262 care professionals) and for travellers to endemic areas [90]. PPSV23 together with PCV13 (13-valent
263 pneumococcal conjugate vaccine) is especially recommended for those with several chronic conditions

264 (HIV infection, chronic respiratory disease, heart failure, etc.). No specific recommendations
265 concerning diphtheria vaccination are given for high risk groups other than professionals.

266 Delivering vaccines to homeless populations has always been a challenge. Combining easy
267 access and education is probably the best approach to vaccination administration programmes in this
268 population. We suggest making vaccines available at homeless shelters or homeless restaurants
269 through medical or paramedical staff. For homeless IDU, the availability of vaccines at syringe-
270 exchange sites could provide more opportunities for them to access vaccination [44]. Additionally, we
271 also suggest applying a rapid serological testing strategy in areas where homeless persons tend to
272 aggregate, including HBsAg detection (for HBV) [91] and IgM/IgG anti-HAV, since a substantial
273 proportion of individuals may already have antibodies against these infections due to past exposure to
274 the viruses or previous vaccination.

275 Because this review was restricted to articles written in general languages such as English,
276 Spanish and French, the data collected are mainly from the North American and European continents.
277 Limitations include the possible lack of articles from Asian and African regions. Despite these
278 limitations, our review showed that implementation of vaccination coverage against communicable
279 diseases in the homeless is a major public health priority. We strongly recommend updating
280 vaccination against HAV, HBV, pneumococcal infection and diphtheria in homeless persons when
281 entering homeless shelters or whenever they are present in a healthcare setting, rather than as a
282 response measure to prevent outbreaks after the first case has occurred.

283 **Funding**

284 No funding.

285 **Conflicts of interest/Competing interests:** The authors have no conflicts of interest.

286 **Author contributions:** TD, VT, TL and PG contributed to data analysis, English or French article
287 reading, interpretation and writing. SC contributed to Spanish article reading, interpretation and
288 writing. PG coordinated the work.

289

290 **References (91/100)**

- 291 [1]. Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging
292 transmissible diseases in the homeless. *Emerg Infect Dis* 2008; 14(9):1353-9.
293 <http://doi.org/10.3201/eid1409.080204>.
- 294 [2]. Ly TDA, Edouard S, Badiaga S, Tissot-Dupont H, Hoang VT, Pommier de Santi V, et al.
295 Epidemiology of respiratory pathogen carriage in the homeless population within two shelters in
296 Marseille, France, 2015-2017: cross sectional 1-day surveys. *Clin Microbiol Infect* 2019;
297 25(2):249.e1-249.e6. <http://doi.org/10.1016/j.cmi.2018.04.032>.
- 298 [3]. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory
299 Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing
300 Homelessness. *MMWR Morb Mortal Wkly Rep* 2019; 68(6):153-156.
301 <http://doi.org/10.15585/mmwr.mm6806a6>.
- 302 [4]. Brouqui P, Raoult D. Arthropod-borne diseases in homeless. *Ann N Y Acad Sci* 2006; 1078:223-
303 235. <http://doi.org/10.1196/annals.1374.041>.
- 304 [5]. World Health Organization. A global brief on vector-borne diseases,
305 <https://apps.who.int/iris/handle/10665/111008> ; 2008 [accessed 20 September 2020].
- 306 [6]. Vahdani P, Hosseini-Moghaddam SM, Family A, Moheb-Dezfouli R. Prevalence of HBV, HCV,
307 HIV and syphilis among homeless subjects older than fifteen years in Tehran. *Arch Iran Med*
308 2009; 12(5):483-487.
- 309 [7]. Robertson MJ, Cousineau MR. Health status and access to health services among the urban
310 homeless. *Am J Public Health* 1986;76:561-563.
- 311 [8]. Andre FA, R Booy , HL Bock , J Clemens , SK Datta , TJ John , et al. Vaccination greatly reduces
312 disease, disability, death and inequity worldwide, [https://www.who.int/bulletin/volumes/86/2/07-
313 040089/en/](https://www.who.int/bulletin/volumes/86/2/07-040089/en/) ; 2008 [accessed 20 September 2020].
- 314 [9]. Borba RC, Vidal VM, Moreira LO. The re-emergency and persistence of vaccine preventable
315 diseases. *An Acad Bras Cienc* 2015; 87(2 Suppl):1311-1322. [http://doi.org/10.1590/0001-
316 3765201520140663](http://doi.org/10.1590/0001-3765201520140663).

- 317 [10]. Hamilton K, Tolfree R, Mytton J. A systematic review of active case-finding strategies for
318 tuberculosis in homeless populations. *Int J Tuberc Lung Dis* 2018; 22(10):1135-1144.
319 <http://doi.org/10.5588/ijtld.17.0784>.
- 320 [11]. Heuvelings CC, Greve PF, de Vries SG, Visser BJ, Bélard S, Janssen S, et al. Effectiveness of
321 service models and organisational structures supporting tuberculosis identification and
322 management in hard-to-reach populations in countries of low and medium tuberculosis
323 incidence: a systematic review. *BMJ Open* 2018; 8(9):e019642. [http://doi.org/10.1136/bmjopen-](http://doi.org/10.1136/bmjopen-2017-019642)
324 [2017-019642](http://doi.org/10.1136/bmjopen-2017-019642).
- 325 [12]. Parriott A, Malekinejad M, Miller AP, Marks SM, Horvath H, Kahn JG. Care Cascade for
326 targeted tuberculosis testing and linkage to Care in Homeless Populations in the United States: a
327 meta-analysis. *BMC Public Health* 2018;18(1):485. <http://doi.org/10.1186/s12889-018-5393-x>.
- 328 [13]. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of
329 latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden
330 countries. *Eur Respir J* 2015;4 6(6):1563-1576. <http://doi.org/10.1183/13993003.01245-2015>.
- 331 [14]. Fuster D, Gelberg L. Community Screening, Identification, and Referral to Primary Care, for
332 Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. *J Community Health* 2019;
333 44(6):1044-1054. <http://doi.org/10.1007/s10900-019-00679-w>.
- 334 [15]. Ly TDA, Dao TL, Hoang VT, Braunstein D, Brouqui P, Lagier JC, et al. Pattern of infections in
335 French and migrant homeless hospitalised at Marseille infectious disease units, France: A
336 retrospective study, 2017-2018. *Travel Med Infect Dis* 2020:101768.
337 <http://doi.org/10.1016/j.tmaid.2020.101768>.
- 338 [16]. Legoupil C, Peltier A, Henry Kagan V, Segouin C, Alberti C, de Massé L, et al. Out-of-Hospital
339 screening for HIV, HBV, HCV and Syphilis in a vulnerable population, a public health
340 challenge. *AIDS Care* 2017; 29(6):686-688. <http://doi.org/10.1080/09540121.2016.1231886>.
- 341 [17]. Doosti-Irani A, Mokhaeri H, Chegini Sharafi A, Aghasadeghi MR, Hajimiragha M, Saki M, et al.
342 Prevalence of HIV, HBV, and HCV and Related Risk Factors amongst Male Homeless People in
343 Lorestan Province, the West of Iran. *J Res Health Sci* 2017; 17(1):e00373.

- 344 [18]. Noska AJ, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Prevalence of Human
345 Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Among Homeless and
346 Nonhomeless United States Veterans. *Clin Infect Dis* 2017; 65(2):252-258.
347 <http://doi.org/10.1093/cid/cix295>.
- 348 [19]. Carvalho PMRDS, Matos MA, Martins RMB, Pinheiro RS, Caetano KAA, Souza MM, et al.
349 Prevalence, risk factors and hepatitis B immunization: helping fill the gap on hepatitis B
350 epidemiology among homeless people, Goiânia, Central Brazil. *Cad Saude Publica*
351 2017;33(7):e00109216. <http://doi.org/10.1590/0102-311X00109216>.
- 352 [20]. Moquillaza-Risco M, León E, Dongo M, Munayco CV. Características sociodemográficas y de
353 salud de los adultos mayores en situación de calle en Lima, Perú. *Rev Peru Med Exp Salud*
354 *Pública* 2015; 32:693–700.
- 355 [21]. Foroughi M, Moayedi-Nia S, Shoghli A, Bayanolhagh S, Sedaghat A, Mohajeri M, et al.
356 Prevalence of HIV, HBV and HCV among street and labour children in Tehran, Iran. *Sex*
357 *Transm Infect.* 2017;93(6):421-423. <http://doi.org/10.1136/sextrans-2016-052557>.
- 358 [22]. Haussig JM, Nielsen S, Gassowski M, Bremer V, Marcus U, Wenz B, et al. A large proportion of
359 people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in
360 eight German cities. *Int J Infect Dis* 2018; 66:5-13. <http://doi.org/10.1016/j.ijid.2017.10.008>.
- 361 [23]. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity
362 and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use
363 disorders in high-income countries: a systematic review and meta-analysis. *Lancet* 2018;
364 391(10117):241-250. [http://doi.org/10.1016/S0140-6736\(17\)31869-X](http://doi.org/10.1016/S0140-6736(17)31869-X).
- 365 [24]. Leiva-Hidalgo J, Madrigal-Méndez A, Salas-Segura D. Seroprevalence of Hepatitis B, C and VIH
366 en Homeless People in Costa Rica. *Rev Costarric Salud Pública* 2013; 22:113–118.
- 367 [25]. Craine N, Hickman M, Parry JV, Smith J, McDonald T, Lyons M. Characteristics of injecting
368 drug users accessing different types of needle and syringe programme or using secondary
369 distribution. *J Public Health (Oxf)*; 32(3):328-235. <http://doi.org/10.1093/pubmed/udp131>.

- 370 [26]. Bal B, Mitra R, Mallick AH, Chakraborti S, Sarkar K. Nontobacco substance use, sexual abuse,
371 HIV, and sexually transmitted infection among street children in Kolkata, India. *Subst Use*
372 *Misuse* 2010; 45(10):1668-1682. <http://doi.org/10.3109/10826081003674856>.
- 373 [27]. Njord L, Merrill RM, Njord R, Pachano JD, Hackett A. Characterizing health behaviors and
374 infectious disease prevalence among Filipino street children. *Int J Adolesc Med Health* 2008
375 ;20(3):367-374. <http://doi.org/10.1515/ijamh.2008.20.3.367>.
- 376 [28]. Vahdani P, Hosseini-Moghaddam SM, Gachkar L, Sharafi K. Prevalence of hepatitis B, hepatitis
377 C, human immunodeficiency virus, and syphilis among street children residing in southern
378 Tehran, Iran. *Arch Iran Med* 2006; 9(2):153-155.
- 379 [29]. O'Carroll A, O'Reilly F. Health of the homeless in Dublin: has anything changed in the context of
380 Ireland's economic boom? *Eur J Public Health*. 2008; 18(5):448-453.
381 <http://doi.org/10.1093/eurpub/ckn038>.
- 382 [30]. Lyons M, Walker M, Craine N, Smith J. Incidence of blood borne viral hepatitis in injecting drug
383 users in South Wales: a de-linked prospective cohort study. *National Public Health Service for*
384 *Wales* 2006; 16 –19.
- 385 [31]. Poulos R, Ferson M, Orr K, Lucy A, Botham S, McCarthy M, Stern J, Dixon J, Murray C, Polis
386 S. Risk factors and seroprevalence of markers for hepatitis A, B and C in persons subject to
387 homelessness in inner Sydney. *Aust N Z J Public Health*. 2007; 31(3):247-51.
388 <http://doi.org/10.1111/j.1467-842x.2007.00056.x>.
- 389 [32]. Stein JA, Andersen RM, Robertson M, Gelberg L. Impact of hepatitis B and C infection on health
390 services utilization in homeless adults: a test of the Gelberg-Andersen Behavioral Model for
391 Vulnerable Populations. *Health Psychol* 2012; 31(1):20-30. <http://doi.org/10.1037/a0023643>.
- 392 [33]. Volf V, Marx D, Pliskova L, Sümegh L, Celko A. A survey of hepatitis B and C prevalence
393 amongst the homeless community of Prague. *Eur J Public Health*. 2008;18(1):44-47.
394 <http://doi.org/10.1093/eurpub/ckm072>.
- 395 [34]. Boyce DE, Tice AD, Ona FV, Akinaka KT, Lusk H. Viral hepatitis in a homeless shelter in
396 Hawai'i. *Hawaii Med J* 2009;68(5):113-115.

- 397 [35]. Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, et al. Methods to
398 recruit and retain a cohort of young-adult injection drug users for the Third Collaborative
399 Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). *Drug Alcohol*
400 *Depend* 2007;91 Suppl 1:S4-17. <http://doi.org/10.1016/j.drugalcdep.2007.05.007>.
- 401 [36]. Moses S, Mestery K, Kaita KD, Minuk GY. Viral hepatitis in a Canadian street-involved
402 population. *Can J Public Health*. 2002;93(2):123-128.
- 403 [37]. Brito VO, Parra D, Facchini R, Buchalla CM. [HIV infection, hepatitis B and C and syphilis in
404 homeless people, in the city of São Paulo, Brazil]. *Rev Saude Publica* 2007; 41 Suppl 2:47-56.
405 Portuguese.
- 406 [38]. Harris HW, Young DM. Care of injection drug users with soft tissue infections in San Francisco,
407 California. *Arch Surg* 2002; 137(11):1217-1222.
408 <http://doi.org/doi:10.1001/archsurg.137.11.1217>.
- 409 [39]. Vallejo F, Toro C, de la Fuente L, Brugal MT, Soriano V, Silva TC, et al. Prevalence of and risk
410 factors for hepatitis B virus infection among street-recruited young injection and non-injection
411 heroin users in Barcelona, Madrid and Seville. *Eur Addict Res* 2008;14(3):116-24.
412 <http://doi.org/10.1159/000130415>.
- 413 [40]. Klinkenberg WD, Caslyn RJ, Morse GA, Yonker RD, McCudden S, Ketema F, et al. Prevalence
414 of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with
415 co-occurring severe mental illness and substance use disorders. *Compr Psychiatry* 2003; 44:293–
416 302. [http://doi.org/10.1016/S0010-440X\(03\)00094-4](http://doi.org/10.1016/S0010-440X(03)00094-4).
- 417 [41]. Noell J, Rohde P, Ochs L, Yovanoff P, Alter MJ, Schmid S, Bullard J, Black C. Incidence and
418 prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. *Sex*
419 *Transm Dis* 2001; 28(1):4-10. <http://doi.org/doi:10.1097/00007435-200101000-00003>.
- 420 [42]. Beech BM, Myers L, Beech DJ, Kernick NS. Human immunodeficiency syndrome and hepatitis
421 B and C infections among homeless adolescents. *Semin Pediatr Infect Dis* 2003;14(1):12-9.
- 422 [43]. Lifson AR, Halcón LL. Substance abuse and high-risk needle-related behaviors among homeless
423 youth in Minneapolis: implications for prevention. *J Urban Health* 2001; 78(4):690-698.
424 <http://doi.org/10.1093/jurban/78.4.690>.

- 425 [44]. Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at
426 syringe exchange sites. *J Urban Health* 2005; 82(1):151-161.
427 <http://doi.org/10.1093/jurban/jti016>.
- 428 [45]. Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM. Viral hepatitis and other infectious
429 diseases in a homeless population. *J Clin Gastroenterol* 2002; 34(4):476-80.
430 <http://doi.org/10.1097/00004836-200204000-00021>.
- 431 [46]. Steele RW, Ramgoolam A, Evans J Jr. Health services for homeless adolescents. *Semin Pediatr*
432 *Infect Dis* 2003; 14(1):38-42. <http://doi.org/10.1053/spid.2003.127216>.
- 433 [47]. Alderman EM, Shapiro A, Spigland I, Coupey SM, Bashir M, Fox AS. Are there risk factors for
434 hepatitis B infection in inner-city adolescents that justify prevaccination screening? *J Adolesc*
435 *Health* 1998; 22(5):389-393.
- 436 [48]. Roy E, Haley N, Lemire N, Boivin JF, Leclerc P, Vincelette J. Hepatitis B virus infection among
437 street youths in Montreal. *CMAJ* 1999; 161(6):689-693.
- 438 [49]. López-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and
439 self-reported injection risk behavior during detention among street-recruited injection drug users
440 in Los Angeles County, 1994-1996. *Addiction* 2001 ;96(4):589-95.
441 <http://doi.org/10.1080/09652140020031638>.
- 442 [50]. Porto SO, Cardoso DD, Queiróz DA, Rosa H, Andrade AL, Zicker F, Martelli CM. Prevalence
443 and risk factors for HBV infection among street youth in central Brazil. *J Adolesc Health*. 1994
444 Nov;15(7):577-81.
- 445 [51]. Wang EE, King S, Goldberg E, Bock B, Milner R, Read S. Hepatitis B and human
446 immunodeficiency virus infection in street youths in Toronto, Canada. *Pediatr Infect Dis J*
447 1991;10(2):130-133.
- 448 [52]. McMahon BJ, Wainwright K, Bulkow L, Parkinson AJ, Lindenbaum M, Wainwright R,
449 Helminiak C. Response to hepatitis B vaccine in Alaska natives with chronic alcoholism
450 compared with non-alcoholic control subjects. *Am J Med* 1990; 88(5):460-464.
451 [http://doi.org/10.1016/0002-9343\(90\)90423-b](http://doi.org/10.1016/0002-9343(90)90423-b).

- 452 [53]. Gelberg L, Robertson MJ, Leake B, Wenzel SL, Bakhtiar L, Hardie EA, et al. Hepatitis B among
453 homeless and other impoverished US military veterans in residential care in Los Angeles. Public
454 Health 2001; 115(4):286-291. <http://doi.org/10.1038/sj/ph/1900783>. PMID: 11464302.
- 455 [54]. Wilson E, Hofmeister MG, McBee S, Briscoe J, Thomasson E, Olaisen RH, et al. Hepatitis A
456 Outbreak Associated with Drug Use and Homelessness — West Virginia, 2018. MMWR Morb
457 Mortal Wkly Rep 2019; 68(14):330–331.
- 458 [55]. Sachdeva H, Benusic M, Ota S, Stuart R, Maclachlan J, Dubey V, Andonov A. Community
459 outbreak of hepatitis A disproportionately affecting men who have sex with men in Toronto,
460 Canada, January 2017–November 2018. Can Commun Dis Rep 2019; 45(10):262-268.
461 <http://doi.org/10.14745/ccdr.v45i10a03>.
- 462 [56]. Peak CM, Stous SS, Healy JM, Hofmeister MG, Lin Y, Ramachandran S, Foster M, Kao A,
463 McDonald EC. Homelessness and Hepatitis A - San Diego County, 2016-2018. Clin Infect Dis
464 2019 ; pii:ciz788. <http://doi.org/10.1093/cid/ciz788>.
- 465 [57]. Kreshak AA, Brennan JJ, Vilke GM, Tolia VM, Caccese M, Castillo EM, et al. A Description of
466 a Health System's Emergency Department Patients Who Were Part of a Large Hepatitis A
467 Outbreak. J Emerg Med. 2018; 55(5):620-626. <http://doi.org/10.1016/j.jemermed.2018.07.031>.
- 468 [58]. Foster M, Ramachandran S, Myatt K, Donovan D, Bohm S, Fiedler J, et al. Hepatitis A Virus
469 Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and
470 Utah, 2017. MMWR Morb Mortal Wkly Rep 2018; 67(43):1208-1210.
471 <http://doi.org/10.15585/mmwr.mm6743a3>.
- 472 [59]. Jahanbakhsh F, Bagheri Amiri F, Sedaghat A, Fahimfar N, Mostafavi E. Prevalence of HAV Ab,
473 HEV (IgG), HSV2 IgG, and Syphilis Among Sheltered Homeless Adults in Tehran, 2012. Int J
474 Health Policy Manag 2018;7(3):225-230. <http://doi.org/10.15171/ijhpm.2017.74>.
- 475 [60]. Fabianova K, Cástková J, Beneš C, Kyncl J, Kriz B. Increase in hepatitis A cases in the Czech
476 Republic in 2008 - preliminary report. Eurosurveillance 2008;13(40).
- 477 [61]. James TL, Aschkenasy M, Eliseo LJ, Olshaker J, Mehta SD. Response to hepatitis A epidemic:
478 emergency department collaboration with public health commission. J Emerg Med 2009;
479 36(4):412-6. <http://doi.org/10.1016/j.jemermed.2007.10.001>.

- 480 [62]. Tjon GM, Götz H, Koek AG, de Zwart O, Mertens PL, Coutinho RA. An outbreak of hepatitis A
481 among homeless drug users in Rotterdam, The Netherlands. *J Med Virol* 2005; 77(3):360-366.
- 482 [63]. Syed NA, Hearing SD, Shaw IS, Probert CS, Brooklyn TN, Caul EO, et al. Outbreak of hepatitis
483 A in the injecting drug user and homeless populations in Bristol: control by a targeted
484 vaccination programme and possible parenteral transmission. *Eur J Gastroenterol Hepatol* 2003;
485 15(8):901-906.
- 486 [64]. Hennessey KA, Bangsberg DR, Weinbaum C, Hahn JA. Hepatitis A seroprevalence and risk
487 factors among homeless adults in San Francisco: should homelessness be included in the risk-
488 based strategy for vaccination? *Public Health Rep* 2009; 124(6):813-817.
- 489 [65]. Ochnio JJ, Patrick D, Ho M, Talling DN, Dobson SR. Past infection with hepatitis A virus among
490 Vancouver street youth, injection drug users and men who have sex with men: implications for
491 vaccination programs. *CMAJ* 2001; 165(3):293-297.
- 492 [66]. Roy E, Haley N, Leclerc P, Cédras L, Bédard L, Allard R. Seroprevalence and risk factors for
493 hepatitis A among Montreal street youth. *Can J Public Health* 2002; 93(1):52-53. Erratum in:
494 *Can J Public Health* 2002; 93(3):232.
- 495 [67]. Queiróz DA, Cardoso DD, Martelli CM, Martins RM, Porto SO, Azevedo MS, et al.
496 [Seroepidemiology of hepatitis A virus infection in street children of Goiânia-Goiás]. *Rev Soc*
497 *Bras Med Trop* 1995; 28(3):199-203. Portuguese.
- 498 [68]. McKee G, Choi A, Madill C, Marriott J, Kibsey P, Hoyano D. Outbreak of invasive
499 *Streptococcus pneumoniae* among an inner-city population in Victoria, British Columbia, 2016-
500 2017. *Can Commun Dis Rep* 2018; 44(12):317-322. <http://doi.org/10.14745/ccdr.v44i12a02>.
- 501 [69]. Beall B, Walker H, Tran T, Li Z, Varghese J, McGee L, et al. Upsurge of conjugate vaccine
502 serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in
503 California, Colorado, and New Mexico. *J Infect Dis* 2020 <http://doi.org/10.1093/infdis/jiaa501>.
- 504 [70]. Schillberg E, Isaac M, Deng X, Peirano G, Wylie JL, Van Caesele P, et al. Outbreak of invasive
505 *Streptococcus pneumoniae* serotype 12F among a marginalized inner-city population in
506 Winnipeg, Canada, 2009-2011. *Clin Infect Dis*; 59(5):651-657.
507 <http://doi.org/10.1093/cid/ciu366>.

- 508 [71]. Tyrrell GJ, Lovgren M, Ibrahim Q, Garg S, Chui L, Boone TJ, Mangan C, PatrickDM, Hoang L,
509 Horsman GB, Van Caesele P, Marrie TJ. Epidemic of invasive pneumococcal disease, western
510 Canada, 2005-2009. *Emerg Infect Dis* 2012; 18(5):733-740.
511 <http://doi.org/10.3201/eid1805.110235>.
- 512 [72]. Vanderkooi OG, Church DL, MacDonald J, Zucol F, Kellner JD. Community-based outbreaks in
513 vulnerable populations of invasive infections caused by *Streptococcus pneumoniae* serotypes 5
514 and 8 in Calgary, Canada. *PLoS One* 2011; 6(12):e28547.
515 <http://doi.org/10.1371/journal.pone.0028547>.
- 516 [73]. Lemay JA, Ricketson LJ, Zwicker L, Kellner JD. Homelessness in Adults with Invasive
517 Pneumococcal Disease (IPD) in Calgary, Canada. *Open Forum Infect Dis* 2019; 6(10). pii:
518 ofz362. <http://doi.org/10.1093/ofid/ofz362>.
- 519 [74]. Marrie TJ, Tyrrell GJ, Majumdar SR, Eurich DT. Invasive Pneumococcal Disease: Still Lots to
520 Learn and a Need for Standardized Data Collection Instruments. *Can Respir J* 2017;
521 2017:2397429. <http://doi.org/10.1155/2017/2397429>.
- 522 [75]. Shariatzadeh MR, Huang JQ, Tyrrell GJ, Johnson MM, Marrie TJ. Bacteremic pneumococcal
523 pneumonia: a prospective study in Edmonton and neighboring municipalities. *Medicine*
524 (Baltimore). 2005; 84(3):147-161.
- 525 [76]. Plevneshi A, Svoboda T, Armstrong I, Tyrrell GJ, Miranda A, Green K, Low D, McGeer A;
526 Toronto Invasive Bacterial Diseases Network. Population-based surveillance for invasive
527 pneumococcal disease in homeless adults in Toronto. *PLoS One* 2009; 4(9):e7255.
- 528 [77]. Mosites E, Zulz T, Bruden D, Nolen L, Frick A, Castrodale L, McLaughlin J, Van Beneden C,
529 Hennessy TW, Bruce MG. Risk for Invasive Streptococcal Infections among Adults
530 Experiencing Homelessness, Anchorage, Alaska, USA, 2002-2015. *Emerg Infect Dis* 2019;
531 25(10). <http://doi.org/10.3201/eid2510.181408>.
- 532 [78]. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's
533 shelters. *Chest* 1991; 99(1):147-151.

- 534 [79]. Dangel A, Berger A, Konrad R, Bischoff H, Sing A. Geographically Diverse Clusters of
535 Nontoxigenic *Corynebacterium diphtheriae* Infection, Germany, 2016-2017. *Emerg Infect Dis*
536 2018; 24(7):1239-1245. <http://doi.org/10.3201/eid2407.172026>.
- 537 [80]. Zasada AA. Nontoxigenic highly pathogenic clone of *Corynebacterium diphtheriae*, Poland,
538 2004-2012. *Emerg Infect Dis*. 2013; 19(11):1870-1972. <http://doi.org/10.3201/eid1911.130297>.
- 539 [81]. Funke G, Altwegg M, Frommelt L, von Graevenitz A. Emergence of related nontoxigenic
540 *Corynebacterium diphtheriae* biotype mitis strains in Western Europe. *Emerg Infect Dis* 1999;
541 5(3):477-780. <http://doi.org/10.3201/eid0503.990326>.
- 542 [82]. Patey O, Bimet F, Riegel P, Halioua B, Emond JP, Estrangin E, et al. Clinical and molecular
543 study of *Corynebacterium diphtheriae* systemic infections in France. Coryne Study Group. *J*
544 *Clin Microbiol* 1997; 35(2):441-445
- 545 [83]. Harnisch JP, Tronca E, Nolan CM, Turck M, Holmes KK. Diphtheria among alcoholic urban
546 adults. A decade of experience in Seattle. *Ann Intern Med* 1989; 111(1):71-82.
547 <http://doi.org/10.7326/0003-4819-111-1-71>.
- 548 [84]. Rodwell TC, Robertson AM, Aguirre N, Vera A, Anderson CM, Lozada R, et al. Pandemic
549 (H1N1) 2009 Surveillance in Marginalized Populations, Tijuana, Mexico. *Emerg Infect Dis*
550 2010;16(8):1292-5. <http://doi.org/10.3201/eid1608.100196>.
- 551 [85]. Badiaga S, Richet H, Azas P, Zandotti C, Rey F, Charrel R, et al. Contribution of a shelter-based
552 survey for screening respiratory diseases in the homeless. *Eur J Public Health* 2009;19(2):157-
553 60. <http://doi.org/10.1093/eurpub/ckn142>.
- 554 [86]. Nyitray AG, Fujimoto K, Zhao J, Giuliano AR, Schneider JA, Hwang LY. Prevalence of and
555 Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly
556 Black Men Who Have Sex With Men, Houston, Texas. *J Infect Dis* 2018;217(5):777-784.
- 557 [87]. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. *Int J Med Sci*.
558 2005;2(1):50-57. <http://doi.org/10.7150/ijms.2.50>.
- 559 [88]. Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, et al. World Health
560 Organization global estimates and regional comparisons of the burden of foodborne disease in
561 2010. *PLoS Med* 2015; 12:e1001923.

- 562 [89]. Centers for Disease control and Prevention. Adult immunization Schedule,
563 <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf> ; 2020
564 [accessed 20 September 2020].
- 565 [90]. Ministère des solidarités et de la santé. Calendrier des vaccinations et recommandations vaccinales
566 2020, [https://vaccination-info-](https://vaccination-info-service.fr/var/vis/storage/original/application/download/calendrier_vaccinations_2020-2.pdf)
567 [service.fr/var/vis/storage/original/application/download/calendrier_vaccinations_2020-2.pdf](https://vaccination-info-service.fr/var/vis/storage/original/application/download/calendrier_vaccinations_2020-2.pdf);
568 2020 [accessed 20 September 2020].
- 569 [91]. European Centre for Disease Prevention and Control. Public health guidance on HIV, hepatitis B
570 and C testing in the EU/EEA, [https://www.ecdc.europa.eu/sites/portal/files/documents/HIV-](https://www.ecdc.europa.eu/sites/portal/files/documents/HIV-hepatitis-B-and-C-testing-public-health-guidance.pdf)
571 [hepatitis-B-and-C-testing-public-health-guidance.pdf](https://www.ecdc.europa.eu/sites/portal/files/documents/HIV-hepatitis-B-and-C-testing-public-health-guidance.pdf); 2018[accessed 20 September 2020].
572

573 Table 1. Hepatitis B infection among homeless persons identified through record review studies.

574 Table 2. Hepatitis A infection among homeless persons identified through record review studies.

575 Table 3. Other vaccine-preventable diseases among homeless persons identified through record review
576 studies.

577 Table 4. Summary of vaccination against HAV, HBV, pneumococcus and diphtheria for French
578 children and adults

579 Figure 1. Flow diagram of included and excluded records.

580 * Two unpublished data sets in our laboratory.

581

2 Table 1. Hepatitis B infection among homeless persons identified through record review studies.

Date of study	Study design	Place of study	Setting	Population at risk/Attack rate (of susceptible)	Age (years) (Mean±SD; range)	Male (%)	Diagnostic tools	Vaccine recommendations from authors	Risk factors identified/ Comments	Mortality rate (%)	Co-infections with other VPD	Previous vaccination rate	References
Before year 2019	Seroprevalence survey	Los Angeles, USA	Homeless shelters and streets	137 HP: HBV infections (57.7%)	Mean±SD: 48.6±8.2	87.5%	Serology			0%			[14]
Between 2017-2018	Seroprevalence survey	Marseille, France	Hospital (infectious disease units)	98 HP hospitalised with different infections: ongoing HBV infection (2%)	Mean±SD: 43.3±16.8	87.6%	Serology (HBsAg, anti-HBs, and anti-HBc)	Need for vaccination		0%			[15]
Year 2016	Seroprevalence survey	France	Streets	341 vulnerable population-patients including HP: HBV infection (6.5%)	Range: 40.0-49.0	About 50.0%	Serology (ELISA test for HBsAg, anti-HBs, and anti-HBc)	Specific anti-HBV vaccination campaigns targeting these specific populations.	Higher rate among HP than general population	0%			[16]
Year 2015	Seroprevalence survey	Khorramabad, Iran	Community centre	307 HP: ongoing HBV infection (1.0%)	Mean±SD: 35.9±9.6	100%	Serology (HBsAg, anti-HBs, and anti-HBc)			0%			[17]
Year 2015	Seroprevalence survey	USA	Hospitals	242740 HP: ongoing HBV infection (1.0%)	Mean±SD: 50.0±16.0	88.9%	Serology (HBsAg)		Higher rate among HP than general population	0%			[18]
Between August 2014 and June 2015	Seroprevalence survey	Goiânia, Brazil	Homeless shelter	359 HP: HBV infection (21.8%) including past (21.2%) and ongoing (0.6%) infection	Mean: 36.0; range 18.0-86.0	81.3%	Serology	Need for health services administrators to provide more opportunities for HBV vaccination	Higher rate among HP than adult population of capitals in the same region of the country. HBV infection was associated with age > 50 (aPR=3.1), black skin colour (1.8), homosexuality (2.6) or bisexuality (1.8).	0%		Estimated through serological test :21.8%	[19]
Between 2012-2014	Retrospective questionnaire survey	Lima, Perú	Homeless shelter	302 HP: HBV infection (approximately 1.6%)	Range: >60.0	82.0%	Questionnaire			0%			[20]
Between 2012-2013	Seroprevalence survey	Tehran, Iran	Street and related organisations (municipality, welfare organisation, police, non-governmental organisations)	1000 street and working children: ongoing HBV (1.7%)	Mean±SD: 15.6±2.5; range: 10.0-18.0	95.0%	Rapid serological testing			0%			[21]
Between 2011 and 2014	Seroprevalence survey	Berlin, Essen, Leipzig, Frankfurt, Cologne, Hanover, Munich,	Four local low-threshold drug services	2077 IDUr including 1369 HP (66.0%); ongoing or past HBV infection (38.0%)	Range: 29.0-41.0	76.7%	Serology (HBsAg, anti-HBs, and anti-HBc)	Need for vaccination, IDUr should be tested and counselled regularly for HBV	Higher rate among HP than general population. HBV infection status was significantly associated with homelessness (OR=1.4, p<0.05)	0%		Questionnaire 32.0%	[22]

		Hamburg, Germany											
Between May 2011 and June 2013	Seroprevalence survey	London, UK	Homeless hostels	489 HP: HBV infection (11.8%) including past (10.4%) and ongoing (1.4%) HBV infection	Range: 30.0-49.0	89.0%	Serology (Architect immunoassay for HBsAg, anti-HBs, and anti-HBc)	HBV vaccination recommended	HBV infection was associated with IDU (aOR=23.7)	0%		Estimated through serological test 28.7%	[23]
Year 2011	Seroprevalence survey	San Jose, Costa Rica	Homeless shelter	100 HP: HBV infection (32.0%)	Mean: 35.0	82.0%	Serology			0%			[24]
Before 2010	Seroprevalence survey	South Wales, UK	Treatment services, needle and syringe programmes, hostels and the street	651 HP: HBV infection (9.4%)	Mean: 29.6, adults	74.0%	Serology			0%			[25]
Year 2008	Seroprevalence survey	Kolkata, India	Community centre	554 street children: HBV infection (around 3%)	Mean: 13.0; range: 11.0-15.0	65.0%	Serology			0%			[26]
Year 2007	Seroprevalence survey	Paco, Philippines	Community centre	179 street children: HBV infection (7.9%)	Range: 8.0-17.0		Serology			0%			[27]
Before 2006	Seroprevalence survey	Tehran, Iran	Community centre	102 street children: ongoing HBV infection (3.0%)	Mean±SD: 10.1±3.0	38.0%	Serology (HBsAg, anti-HBs, and anti-HBc)			0%			[28]
Between April-July 2007	Seroprevalence survey	Tehran, Iran	Community centre	202 HP: HBV infection (34.7%)	Mean±SD: 45.0±17.7; range: >15.0	100%	Serology (HBsAg, anti-HBs, and anti-HBc)		HBV infection was positively associated with intravenous drug abuse and imprisonment	0%			[6]
Year 2005	Seroprevalence survey	Dublin, Ireland	Temporary accommodation	363 HP: HBV infection (5.0%)	Adults >18.0	61.0%	Serology		HBV infection was positively associated with IDU	0%			[29]
Between 2004-2006	Seroprevalence survey	South Wales, UK		421 IDU: including 39% HP: HBV infection (13%)	Mean: 30.0		Serology			0%	54%		[30]
Between 2003-2005	Seroprevalence survey	Sydney, Australia	Medical clinic for homeless	189 HP: HBV infection (33.6%) including past (32.0%) and ongoing (1.6%) infection	Mean: 42, range: 18.0-74.0	86.0%	Serology (HBsAg, anti-HBs, and anti-HBc)	Need for HBV vaccination	Higher rate among HP than general population. Past HBV infection was positively associated with IDU.	0%	About 6.3% (12/189) were HAV-past HBV co-infection		[31]
Year 2005	Seroprevalence survey	Prague, Czech Republic	Community centre for youth and adults	98 HP: HBV infection (7.2%)	Range: 16.0->50.0	89.7%	Serology (HBsAg, HBeAg, anti-HBs, and anti-HBc) and qPCR	Negative subjects will be offered vaccination	Higher rate among HP than general population. HBV infection was positively associated with IDU.	0%			[32]
Year 2003-2004	Seroprevalence survey	Skid Row, Los Angeles, USA	19 shelter programmes at 10 locations and 22 meal	534 HP: HBV infection (31.0%)	Mean: 46.0	80.0%	Serology		HBV infection was positively associated with IDU, alcohol use, older age, and risky sexual	0%			[33]

			programmes at 9 locations						behaviour					
Year 2003	Seroprevalence survey	Hawaii, USA	Homeless shelters	40 HP: ongoing HBV (2.5%)	Adults			Serology (HBsAg, anti-HBs, and anti-HBc)		0%				[34]
Years 2002-2004	Seroprevalence survey	Baltimore, Chicago, Los Angeles, New York, and Seattle, USA	Community centres for IDU administration	3285 IDUr including 47.6% HP: HBV infection (22.4%)	Mean: 23.8 15.0-30.0			Serology (HBsAg, anti-HBs, and anti-HBc)	Need for HBV vaccination	0%				[35]
Years 2002-2003	Seroprevalence survey	Canada	Streets	533 street-involved persons: HBV infection (12.0%) including past (9.0%) and ongoing (3.0%) infection	Mean: 25.7; range: 11.0-65.0	47.0%		Serology (HBsAg, anti-HBs, and anti-HBc)	Successful HBV vaccination can be achieved in the majority of this population.	Higher rate among HP than general population.	0%			[36]
Years 2002-2003	Seroprevalence survey	São Paulo, SP, Brazil	Five homeless shelters	330 sheltered HP: HBV infection (33.9%) including previous (30.6%) and ongoing (3.3%) infection	Mean: 40.2; range: 18.0-72.0	80.9%		Serology (ELISA test for HBsAg, anti-HBs, and anti-HBc)	Vaccination against hepatitis B must be implemented to reduce infection in this vulnerable group.		0%			[37]
Between 2001-2002	Seroprevalence survey	San Francisco, California, USA	Surgical service for soft tissue infection	3365 IDUr including 30.0% HP: HBV infection (12.0%)	Mean ±SD: 40.0 ±5.0	70.0%		Serology			0%			[38]
Years 2001-2003	Seroprevalence survey	Barcelona, Madrid and Seville, Spain	Health and social centres	949 heroin users including 14.0% HP: HBV infection (17.2%)	Mean: 25.7; range: 18-30	72.7%		Serology (HBsAg, anti-HBs, and anti-HBc)	The vaccination strategy urgently needs to be reinforced and redesigned.	HBV infection was positively associated with IDU.	0%			[39]
Between 2000-2015	Seroprevalence survey	Marseille, France	Two homeless shelters	1890 HP: previous (35.7%) and ongoing (4.1%) HBV infection	Mean ±SD: 43.1 ±16.4; range: 18-86	95.2%		Serology (HBsAg, anti-HBs, and anti-HBc) and sequencing	Need for HBV vaccination	Higher rate among HP than general population. HBV infection was positively associated with individuals born in sub-Saharan African or Asian countries as compared to Europe	0%		Estimated through serological test :6.5%	Unpublished data
Between June-October 2000.	Seroprevalence survey	Baltimore, Marilance, USA	Hospitals, social service agencies, emergency shelters, soup kitchens, and street locations	172 HP with concomitant severe mental illness and substance use disorders: HBV infection (33%)	Mean: 39.8	77.9%		Serology (HBsAg, anti-HBs, and anti-HBc)	Vaccination should be offered to HP with severe mental illness and substance use disorders		0%			[40]
Years 2000s	Seroprevalence survey	A large northwestern US city, USA	Streets	536 adolescent HP: HBV infection (3.4%)	Mean: 18.8 ±1.6; range: 14.0-20.0	59.5%		Serology (HBsAg, anti-HBs, and anti-HBc)	Need for HBV vaccination	HBV infection was positively associated with self-reported IDU	0%			[41]

Years 2000s	Seroprevalence survey	USA	Temporary shelters	150 HP adolescents: HBV infection (17.0%)	Range: 14.0-23.0	70.0%	Serology (ELISA test for HBsAg, anti-HBs, and anti-HBc)	HBV vaccination programmes targeting homeless youth	Higher rate among HP than most previous reports such as Porto et al., 1994 about street youth. HBV infection was positively associated with sexual preference (homosexual/bisexual vs heterosexual) and ages	0%			[42]
Between 1998-1999	Retrospective questionnaire survey	Minneapolis, Minnesota, New York, USA	Coffee houses and drop-in centres	105 street youths: HBV infection (6.0%)	Range: 15.0-22.0	60.0%	Questionnaire	Recommendation for HBV vaccination		0%		43% reporting receiving vaccine	[43]
Between 1998-2001	Seroprevalence survey	New Haven, USA	Community Health Service	212 IDUr, including 76 HP (36.0%): HBV infection (37%) including past (33.3%) and ongoing (4.7%) infection	Mean: 38.2	69.0%	Serology (ELISA test for HBsAg, anti-HBs, and anti-HBc)	Syringe exchange sites were more highly motivated to complete vaccination.	Completing three vaccinations was positively associated with homeless IDUr	0%		>66% for 3 doses	[44]
Between 1995-2000	Seroprevalence survey	Stanford, California, USA	Domiciliary care for homeless veterans	829 HP: ongoing HBV infection (1.2%)	Mean: 43.5 ± 7.0 range: 18.0-64.0	96.0%	Serology (HBsAg, anti-HBs, and anti-HBc)			0%			[45]
Between 1995-2002	Seroprevalence survey	New Orleans, Louisiana, USA	Emergency shelters	4005 HP adolescents: ongoing HBV infection (0.6%)	Range: 16.0-21.0	32.0%	Serology	Application of vaccination		0%		Questionnaire 9%	[46]
Year 1996	Seroprevalence survey	New York, USA	Inner-city hospital-based adolescent clinic or a health facility	53 HP: HBV infection (44.4%)	Mean: 18.0; range: 13.0-21.0	26.0%	Serology (HBsAg, anti-HBs, and anti-HBc)	Homelessness may be indications for pre-vaccination screening for HBV infection in adolescents	Higher rate among HP than non-HP	0%			[47]
Between December 1995 and September 1996	Seroprevalence survey	Montreal, Canada	Services of street youth agencies	437 street youths: HBV infection (9.2%)	Range: 14.0-25.0	69.3%	Serology (HBsAg, anti-HBs, and anti-HBc)	Early and complete HBV vaccination among this vulnerable population is urgently needed.	Higher rate among HP than general population, aged 14 to 30 years. HBV infection was positively associated with age (>18.0 years), with IDU, those having a sexual partner who had unspecified hepatitis.	0%		38.5% (at least one dose) and 11.8% (3 doses)	[48]
Between 1994-1996	Seroprevalence survey	Los Angeles County, California, USA	Streets	642 participants including 36.0% HP: HBV infection (83.3%) including past (80.3%) and ongoing (3.1%) infection	Mean: 43.0; range: 18.0-70.0	71.0%	Serology (HBsAg, anti-HBs, and anti-HBc)		Past infection was positively associated while in detention and having been ever arrested for possession of IDU paraphernalia	0%			[49]
Between September 1990 and July 1991	Seroprevalence survey	Brazil	Market places, streets and state institutions	496 street adolescents: HBV infection (15.5%) including past (13.5%) and ongoing (2.0%) infection	Mean: 13.6; range: 9.0-20.0	97.7%	Serology (EIA)	Baseline information for policy changes in hepatitis B prevention	Street-based youth had a higher HBV marker-positive rate when compared to home-based teens (OR = 4.1, p<0.05)	0%			[50]

Years 1990s	Seroprevalence survey	Toronto, Canada	Hospital	44 street youths: Ongoing infection (2.0%)	Mean: 15.7 ± 1.8	18.2%	Serology (HBsAg, anti-HBs, and anti-HBc)	The difficulty in ensuring vaccine coverage in this population would support calls for including hepatitis B vaccination as part of childhood immunisation.	HBV infection was likely to be higher among HP compared to controls (0%)	0%			[51]
Before 1990	Seroprevalence survey	Alaska, USA	Hospital	64 alcoholics including HP: HBV infection (33.4%)	Mean: 35.0	55.0%	Serology (HBsAg, anti-HBs, and anti-HBc)	Need for vaccination	HBV infection was likely to be higher among HP compared to controls (34.4% versus 11.7%)	0%			[52]
Between Feb 1988 and July 1993	Seroprevalence survey	West Los Angeles, USA	Residential setting	370 male HP: HBV infection (30.8%) including ongoing (3.0%) and past (30.8%) infection	Mean: 44.1	100%	Serology (ELISA test for HBsAg, anti-HBs, and anti-HBc)	Offer vaccination to HP adults	HBV infection was positively associated with non-white ethnicity, age (>45.0 years), history of regular heroin use, history of drug detoxification	0%			[53]

3 **Abbreviations.** SD, standard deviation; VPD: vaccine-preventable diseases; HP, homeless persons; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface antigen;
4 anti-HBc, antibody to hepatitis B core antigen; ELISA, Enzyme-linked immunosorbent assay; aPR: adjusted prevalence ratio; IDU, Injected drug use; IDUr, Injected drug users; OR, Odds-ratio; aOR, adjusted
5 Odds-ratio; HAV, hepatitis A virus; EIA, enzyme immunoassay

6

7 Table 2. Hepatitis A infection among homeless persons identified through record review studies.

Date of study	Study design	Place of study	Setting	Population at risk/Attack rate (of susceptible)	Age (Mean±SD; range)	Male (%)	Diagnostic tools	Vaccine recommendations from authors	Risk factors identified/ Comments	Mortality rate (%)	Co-infections with other VPD	Previous vaccination rate	References
Between January-August 2018	Outbreak investigation	West Virginia, USA	Hospitals	664 confirmed HAV cases, including 100 HP (15.1%)	Mean: 37.0; range: 14.0-77.0	60.0%	Serology (IgM anti-HAV) and then genotyping	Support the recent national ACIP recommendation ¹		About 0.1%			[54]
Between 2017-2018	Outbreak investigation	Toronto, Canada	Hospitals	42 confirmed HAV cases (MSM), including 4 HP (10.0%)	Mean: 38.0	79.0%	Serology (IgM anti-HAV) and then genotyping	Support the recent national ACIP recommendation		0%			[55]
Between 2016-2018	Outbreak investigation	San Diego County, USA	Hospitals	589 confirmed HAV cases, including 291 HP (49.0%)	Mean: 43.0		Serology (IgM anti-HAV) and then confirmation by RT-PCR	Support the recent national ACIP recommendation		4.8%	34.0% were HAV-HBV (or HCV) co-infection	Questionnaire: 73.0%	[56]
Between 2016-2018	Outbreak investigation	San Diego County, USA	Emergency department	133 confirmed cases, including HP (64.7%)	Mean: 45.1	68.4%	Serology			6.0%			[57]
Year 2017	Outbreak investigation	California, Kentucky, Michigan, and Utah, USA	Hospitals	1521 confirmed HAV cases, including 524 HP (34.5%)	Mean: 36.0-42.0; range: <1.0-90.0	About 66.0%	Serology (IgM anti-HAV) and then genotyping	Support the recent national ACIP recommendation		3.0%	3.0% were HAV-HBV co-infection	Questionnaire: About 54.0%	[58]
Between June-August 2012	Seroprevalence survey	Tehran, Iran	Homeless shelter, streets, in parks, or in public places	569 HP: anti-HAV positivity (94.3%)	Mean: 42.0	82.4%	Serology (anti-HAV)		Prevalence of HAV significantly was higher in men	0%			[59]
Between May-September 2008	Outbreak investigation	Prague, Czech Republic	Hospitals	602 confirmed HAV cases, including 474 persons (78.7%) in risk groups (e.g. HP, alcoholics)	Range: 0-14.0 (7.6%); 15.0-64.0 (78.5%); >65.0 (13.9%)	About 60.0%	laboratory-confirmed in accordance with the European Union case definition ²	Post-exposure prophylaxis by vaccine was provided to HAV contacts in foci and preventive vaccination was offered to HP		0%			[60]
Year 2004	Outbreak investigation	Boston, USA	Medical centre	136 confirmed HAV cases, including HP (61.0%)	Adults >16.0	64.0%		Need for vaccination		0%			[61]
Between January-June 2004	Outbreak investigation	Rotterdam, The Netherlands	Municipal Health Service	93 confirmed HAV cases, including 15 HP (16.2%) accounting for 0.8% (of 1800 HP)	Mean: 32.0; range: 21.0-44.0		Serology (IgG and IgM anti-HAV)	Large-scale vaccination strategy prevented its further spread.	HAV subtype 3a in 12 HP in a family	0%			[62]
Between 2003-2005	Seroprevalence survey	Sydney, Australia	Medical clinic for homeless	189 HP: anti-HAV positivity (40.0%)	Mean: 42.0; range: 18.0-74.0	86.0%	Serology (total anti-HAV)	Need for HAV vaccination		0%	About 6.3% (12/189) were HAV-past HBV co-infection		[31]
Between 2002-2004	Seroprevalence survey	Baltimore, Chicago, Los Angeles, New York, and	Centres for IDU administration	3285 IDU: including 47.6% HP: anti-HAV positivity (19.3%)	Mean: 23.8; range: 15.0-30.0		Serology (total anti-HAV)	Need for HAV vaccination		0%			[35]

		Seattle, USA											
Between 2002-2003	Seroprevalence survey	Canada	Streets	533 street-involved persons: IgG anti-HAV positivity (53%)	Mean: 25.7; range: 11.0-65.0	47.0%	Serology (IgG anti-HAV)	Successful HAV vaccination can be achieved in the majority of this population.		0%			[36]
Year 2000	Outbreak investigation	Bristol, UK	Hospital	123 confirmed HAV cases, including 28 HP (23.0%)	Mean: 25.0; range: 2.0-74.0	About 70.0%	Serology (IgM anti-HAV)	Administration of a targeted vaccination, education and liaison programme applied; vaccination of these groups is feasible and acceptable in an outbreak situation		0%			[63]
Between 1999-2000	Seroprevalence survey	San Francisco, USA	Shelter and meal programmes	1138 HP: anti-HAV positivity (52.0%)	Range 26.0-68.0	75.0%	Serology (IgG and IgM anti-HAV) and questionnaire data	Need for vaccination		0%			[64]
Between March-August 1998	Seroprevalence survey	Vancouver, Canada	Street outreach clinics	111 street youths: anti-HAV positivity (6.3%)	Mean±SD: 19.6±2.7		Ultrasensitive capture enzyme immunoassay-based method (Salivary sample)	Need to develop routine vaccination programmes	Anti-HAV was positively associated with those reporting IDU	0%			[65]
Between 1995-1996	Seroprevalence survey	Montreal, Canada	Services of Montreal street youth agencies	427 street youths: anti-HAV positivity (4.7%)	Range: 14.0-25.0	69.3%	Serology (total anti-HAV)	Vaccination against HAV is actively promoted among Montreal street youth.	Anti-HAV positivity was associated with those having had sexual partner(s) with history of unspecified hepatitis or insertive anal penetration	0%			[66]
Between 1991-1992	Seroprevalence survey	Goiânia-Goiás, Brazil	Day-care centres	397 street youths: anti-HAV positivity (69.7%)	Range: 7.0-21.0	91.2%	Serology (IgG and IgM anti-HAV)	Vaccine strategy in developing countries		0%			[67]

8 **Abbreviations.** SD, standard deviation; VPD: vaccine-preventable diseases; HP, homeless persons; HAV, hepatitis A virus; anti-HAV, antibody to hepatitis A virus; ACIP, Advisory Committee on Immunization
9 Practices; MSM, men who have sex with men; RT-PCR, real time-polymerase chain reaction; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, Injected drug use; IDUr, Injected drug users;

0 ¹ ACIP recommendation: All persons aged 1 year and older experiencing homelessness should be routinely immunised against hepatitis A. Routine vaccination consists of a 2-dose schedule or a 3-dose schedule
1 when administered with combined hepatitis A and B vaccine.

2 ² European Union case definition for HAV (source): <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945&from=EN#page=22>.

3

4 Table 3. Other vaccine-preventable diseases among homeless persons identified through record review studies.

Date of study	Study design	Place of study	Setting	Population at risk/Attack rate (of susceptible)	Age (Mean±SD; range)	Male (%)	Diagnostic tools	Vaccine recommendations from authors	Risk factors identified/ Comments	Mortality rate (%)	Co-infections with other VPD	Previous vaccination rate	References
A. Pneumococcal infection													
Year 2018	Molecular prevalence survey	Marseille, France	Two homeless shelters	98 HP: Pneumococcal nasopharyngeal carriage (15.5%)	Mean±SD: 39.3 ± 17.6	100%	qPCR	Need to increase vaccination rate	Pneumococcal carriage prevalence was likely to be higher than control groups	0%		Questionnaire: 3.1%	Unpublished data
Autumn and winter of 2016–2017	Outbreak investigation	Victoria, British Columbia, Canada	Hospitals	84 HP with confirmed IPD	Mean: 56.3	61.0%	Culture isolation and serotyping (Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin)	Pneumococcal vaccination coverage is needed among this marginalised population.	Positive association between serotype 4 IPD and homelessness (OR=4.9; p<0.01)	11.9%		Questionnaire: 13.0%	[68]
Between 2015-2017	Molecular prevalence survey	Marseille, France	Two homeless shelters	477 HP: Pneumococcal nasopharyngeal carriage (12.4%)	Mean±SD: 43.6±16.0; range: 18.0-84.0	100%	qPCR	Need to increase vaccination rate	Pneumococcal carriage was positively associated with respiratory symptom presentation.	0%	0.2% were <i>S. pneumococcus</i> -influenza virus co-carriage		[2]
Between 2010-2018	Outbreak investigation	California, Colorado, and New Mexico, USA	Hospitals	325 serotype 4 cases among adults, including HP (36.0%)	Adults ≥ 17.0		Culture isolation and whole-genome sequencing	Future vaccine policy discussions should include homelessness as an indication for pneumococcal vaccines.					[69]
Between September 2009 and January 2011	Outbreak investigation	Winnipeg, Canada	Hospitals	169 patients with confirmed IPD, including 20 HP (11.8%)	Mean: 42.0; range: 0-94.0	About 58.0%	Culture isolation, PFGE, MLST, MLVA	Need to vaccinate unvaccinated individuals who are homeless or use illicit drugs	Serotype 12F patients were more likely to report homelessness (OR=12.7; p<0.05).	0%		Questionnaire: 37.0%	[70]
Between 2005-2009	Outbreak investigation	Alberta, Canada	Hospitals	1112 patients with confirmed IPD, including 85 HP (7.6%)	Mean±SD: 45.4±22.5	About 59.3%	Culture isolation from site such as blood, CSF, pleural fluid, biopsy tissue, joint aspiration, pericardial fluid, or peritoneal fluid	Need for vaccination programme for HP		About 11.3%			[71]
Between 2005-2007	Outbreak investigation	Calgary, Canada.	Hospitals	207 patients with confirmed IPD (strain ST5 or ST8), including HP (48.8%)	Adults ≥ 16.0		Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin and pneumococcal antibody agglutination and susceptibility	Vaccination for homeless	Individuals with ST5 or ST8 IPD were more likely to be homeless (% [OR] 53.0% [4.4] or 43.0% [2.6], respectively).	0%			[72]

							testing (broth microdilution).						
Between 2000-2016	Outbreak investigation	Calgary, Canada	Hospitals	1729 patients with confirmed IPD, including 321 HP (18.8%)	Mean±SD: 45.0±27.0	78.8%	Culture isolation and serotyping (Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin)	The most effective public health intervention for HP to specifically prevent IPD is vaccination (both PPV23 and PCV13 vaccinations)	HP were younger, more often male, smokers, alcohol abusers, illegal drug users, and had a primary diagnosis of pneumonia when compared with non-homeless.	6.9%			[73]
Between 2000-2014	Outbreak investigation	Alberta, Canada	Hospitals	2435 IPD patients, including 184 HP (7.4%)	Mean±SD: 54.2±17.8	56.7%	Culture isolation from site such as blood, CSF, pleural fluid, biopsy tissue, joint aspiration, pericardial fluid, or peritoneal fluid	Vaccination and other intervention programmes should have a high benefit in this population.		About 15.6%			[74]
Between November 2000 to November 2002	Outbreak investigation	Alberta, Canada	Hospitals	129 confirmed BPP patients, including 6 HP (4.7%)	Adults ≥17.0	About 70%	Culture isolation and serotyping (Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin)	HP should be targeted for vaccination.	The attack rate of BPP among HP was 266 per 100,000 person years, 27 times that of the general population. Current smoking, substance abuse, alcohol abuse was predictive of BPP				[75]
Between January 2002 and December 2006	Outbreak investigation	Toronto, Canada	Hospitals	Estimation of 5050 HP in Toronto: 69 (1.4%) cases with confirmed IPD including 27 (0.5%) PP	Mean: 45.0; range: 27.0-74.0	89.0%	Culture isolation and serotyping (Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin)	Vaccination may be effective in reducing the risk.	HP with IDP were more often smokers, those with HIV infection and liver disease when compared to non-HP	15.0%	Questionnaire: 9.0%		[76]
Between 2002-2015	Outbreak investigation	Anchorage, Alaska, USA	Hospitals	Estimation of 970 HP in Anchorage: 84 cases (8.7%) with confirmed IPD	Mean±SD: 48.0±9.0	65.0%	Culture isolation and serotyping	Increasing the availability of pneumococcal vaccine in HP could improve the health of this vulnerable group.	Compared to general population (0.16%), HP were younger, more often alcohol abusers when compared to non-HP.	0%			[77]
Between April 1988 and March 1989	Outbreak investigation	Paris, France	Hospitals	39 HP for acute pneumonia: <i>Streptococcus pneumoniae</i> serotype 1, resistant to cotrimoxazole, was isolated in 29	Mean±SD: 46.0±11.0; range 27.0-74.0	100%	Culture isolation and serotyping (Gram stain, colony morphology on blood agar, bile solubility, susceptibility to optochin)	Sheltered residents would benefit from pneumococcal vaccination.		2.6%	Questionnaire: 10.0%		[78]

				patients (74.0%). Blood cultures were positive in 24 (61.0%).									
B. Diphtheria													
Between 2016–2017	Molecular investigation of outbreak	Germany	Hospitals	76 infected persons, including 25 (32.9%) HP or those reporting drug abuse; strain ST8 (53.9%)	Mean: 45.0	83.0%	Culture isolation and genotyping			0%			[79]
Between 2004–2012	Molecular investigation of outbreak	Poland	Hospitals	18 confirmed diphtheria cases, including 31.0% HP: genotype ST8 (100%)	Range: 16.0- >71.0		Culture, MLST and PFGE	Homelessness and alcohol were identified as risk factors.		0%			[80]
Between 1996-1997	Outbreak investigation	Switzerland, Germany, France.	Hospitals	17 patients, including 2 HP (11.8%)	Mean: 40.0; range: 30.0-58.0	100%	Culture: Isolation from skin or subcutaneous infections			0%			[81]
Between 1987-1993	Outbreak investigation	France	Hospitals	40 patients with systemic infections, including 13 HP (31.7%)	Mean: 38.0; range: 4.0-87.0	75.0%	culture isolation (blood, osteoarticular, perineal, nasopharyngeal, respiratory tract, skin samples)	Homelessness and alcohol were identified as risk factors.		36%			[82]
Between 1972-1982	Outbreak investigation	Seattle, Washington, U.S.A.	Hospitals	1100 infected persons, including 95.0% HP	Mean: 37.3 (19 HP children + 1081 adults)	About 91.0%	Culture (nasopharyngeal, respiratory tract, skin samples and environmental samples)	Need for vaccination within 10 years	Alcoholic urban HP associated with poor hygiene, crowding, season, contaminated fomites, underlying skin disease, hyperendemic streptococcal pyoderma, and introduction of new strains from exogenous reservoirs.	0.9%			[83]
C. Seasonal influenza													
Between 2017-2018	Molecular prevalence survey	Marseille, France	Hospital (infectious disease units)	98 HP hospitalised for different reasons: influenza virus infection (3.0%)	Mean ±SD: 43.3 ± 16.8	87.6%	qPCR	Need for seasonal flu vaccination		0%			[15]

Between 2015-2017	Molecular prevalence survey	Marseille, France	Two homeless shelters	477 HP: Nasopharyngeal influenza carriage (1.7%)	Mean ±SD: 43.6 ±16.0; range: 18.0-84.0	100%	qPCR	Need for seasonal flu vaccination	Respiratory viral carriage including influenza viruses was positively associated with respiratory symptoms and signs.	0%	0.2% were <i>S. pneumoniae</i> -influenza virus co-carriage	15.1%	[2]
Between May-November 2009	Molecular prevalence survey	Tijuana, Mexico	Outreach units and community clinics	303 persons from marginalised Populations, including HP: H1N1 infection (2.0%)	Mean: 35.0; range: 29.0-43.0	62.0%	qPCR	Need for seasonal flu vaccination		0%		8.9%	[84]
Year 2005	Molecular prevalence survey	Marseille, France	Two homeless shelters	225 HP: Influenza carriage (1.0%)	Mean: 41.0; range: 7.0-76.0	94.0%	qPCR	Need for seasonal flu vaccination		0%			[85]
D. Human papillomavirus													
Between 2014-2016	Molecular prevalence survey	Houston, Illinois, USA	Community centres	130 MSM, including 22.6% HP; 75.0% had at least 1 high-risk HPV type	Range: 18.0-29.0	100%	Consensus PCR for HPV genotyping	Black MSM would benefit from increased HPV vaccination efforts		0%			[86]
Between 1995-2002	Epidemiological survey	New Orleans, Louisiana, USA	Emergency shelter	4005 HP adolescents: HPV infection (2.0%) among 2723 females	Range: 16.0-21.0	32.0%	Pap smear testing						[46]

5 **Abbreviations.** SD, standard deviation; VPD: vaccine-preventable diseases; HP, homeless persons; IPD, Invasive pneumococcal disease; PFGE, Pulsed-field gel electrophoresis; MLST, Multi-locus sequencing
6 typing; MLVA, multiple-locus variable number tandem repeat analysis; CFS, cerebrospinal fluid; OR, Odds-ratio; BPP, Bacteraemic pneumococcal pneumonia; PP, pneumococcal pneumonia; qPCR: real time
7 polymerase chain reaction; HPV, Human papillomavirus; MSM, men who have sex with men.

8

9 **Table 4.** Summary of vaccination against HAV, HBV, pneumococcus and diphtheria for French children and adults¹

Vaccines	General recommendations	Specific recommendations
Hepatitis B virus	<p>Primary vaccination is mandatory for all children born after 01 January 2018. Application of 2- or 3-doses depending on type of vaccine</p> <ul style="list-style-type: none"> - Dose 1: from 2 months - Dose 2: 1 month after dose 1 - Dose 3: 6 months after dose 2 	<p>For high risk groups</p> <ul style="list-style-type: none"> - Preschool children in community settings - Newborns whose mothers are carriers of the HBs antigen as well as those born in Guyana or Mayotte - Children and adults in psychiatric institutions - Children and adolescents in institutions for infants or young disabled persons - Persons having sex with multiple partners, having a current or past STI or exposed to STIs - Parenteral or intranasal drug users - Travelers in countries of medium or high endemic disease - Persons residing in areas of moderate or high endemic disease - Persons who are candidates for organ, tissue or cell transplants - Persons in close proximity to someone with acute or chronic hepatitis B - Sexual partners of a person infected with hepatitis B virus or carrier of the HBs antigen - Persons who accumulate exposure factors to the hepatitis B virus - Persons with chronic liver disease - Persons infected with HIV or hepatitis C virus <p>For professionals</p> <ul style="list-style-type: none"> - Medical and pharmaceutical professions: doctor, dental surgeon, pharmacist, midwife - Other health professions: nurse, specialist nurse, masseur-physiotherapist, pedicure-podiatrist, medical electroradiology manipulator, nurse's aide, ambulance driver, childcare assistant, biomedical analysis technician, dental assistant - The abolition of age requirements for the control of immunisation - Establishing proof of immunisation by systematic serological testing - Persons entering training courses for the professions listed in the order of March 6, 2007
Hepatitis A virus	<ul style="list-style-type: none"> - 1 dose now and 1 dose injected 6-36 months after dose 1 	<p>For high risk groups</p> <ul style="list-style-type: none"> - Children aged >1 year whose at least one of member in family originating from a country with a high anti-HAV antibody prevalence - Patients with cystic fibrosis or liver disease - New young received into institutions for infants or handicapped persons - Men having sex with men. - Travelers in countries of medium or high endemic disease <p>For professionals</p> <ul style="list-style-type: none"> - Persons taking care of children (for example nursery staff, childminders) - Persons working in collective reception structures for disabled people - Persons responsible for the treatment of wastewater and sewers
Invasive pneumococcal diseases	<p>Primary vaccination is mandatory for all children born after 01 January 2018.</p> <ul style="list-style-type: none"> - < 2 years: 3 doses of PCV13 at 2, 4 and 11 	<p>For high risk groups</p> <p>a) Immunocompromised patients (patients concerned by the vaccination recommendations for the immunocompromised)</p>

	<p>months; 1 dose of PPSV23 at 24 months</p> <ul style="list-style-type: none"> - 2-5 years: 2 doses of PCV13 now and after 2 months; 1 dose of PPSV23 2 months after dose 2 - >5 years: 1 dose of PCV13 now and 1 dose of PPSV23 after 2 months 	<ul style="list-style-type: none"> - Asplenic or hyposplenic (including major sickle cell syndromes). - With hereditary immune deficiencies. - With HIV infection. - With a solid tumour or malignant haemopathy. - With transplantation or awaiting solid organ transplantation. - Transplanted haematopoietic stem cells. - Treated with immunosuppressant, biotherapy and/or corticosteroid therapy for a chronic autoimmune or inflammatory disease. - Nephrotic syndrome. <p>b) Non-immunocompromised patients (with an underlying disease predisposing to the occurrence of invasive pneumococcal diseases)</p> <ul style="list-style-type: none"> - With cyanogenic congenital heart disease, heart failure. - With chronic respiratory failure, obstructive pulmonary disease, emphysema. - With severe asthma under continuous treatment. - With renal failure. - With chronic liver disease of alcoholic or non-alcoholic origin. - With diabetes uncontrolled by simple diet. - With an osteo-meningeal breach, a cochlear implant or candidate for a cochlear implantation.
<p>Diphtheria</p>	<p>Primary vaccination is mandatory for all children born after 01 January 2018.</p> <ul style="list-style-type: none"> - Dose 1: at 2 months old - Dose 2: at 4 months old - Dose 3: at 11 months old 	<p>For professionals</p> <p>-Revaccination at age 25, 45 and 65 years, depending on professional activities, with a vaccine containing a reduced dose of diphtheria toxoid.</p>

0 **Abbreviations:** STI, sexually transmitted infections; HIV, human immunodeficiency virus; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
1 1. According to French vaccination guidelines: Ministère des solidarités et de la santé. Calendrier des vaccinations et recommandations vaccinales 2020 Mars. Available at [https://solidarites-](https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_29juin20.pdf)
2 [sante.gouv.fr/IMG/pdf/calendrier_vaccinal_29juin20.pdf](https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_29juin20.pdf).

